Treatment of Scleroderma-interstitial Lung Disease with Cyclophosphamide is Associated with Less Progressive Fibrosis on Serial Thoracic High-resolution CT Scan Than Placebo: Findings from the Scleroderma Lung Study

Overview

Journal Chest

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2009 Nov 7

PMID 19892673

Citations 49

Authors

Jonathan Goldin

Robert Elashoff

Hyun J Kim

Xaiohong Yan

David Lynch

Diane Strollo

Michael D Roth

Philip Clements

Daniel E Furst

Dinesh Khanna

Srainnapha Vasunilashorn

Gang Li

Donald P Tashkin

Affiliations

Soon will be listed here.

Abstract

Background: The Scleroderma Lung Study (SLS) demonstrated significant treatment-associated improvements in pulmonary function and symptoms when patients with scleroderma-related interstitial lung disease (SSc-ILD) were treated with a 1-year course of cyclophosphamide (CYC) in a randomized, double-blinded, placebo-controlled clinical trial. This study examined thoracic high-resolution CT (HRCT) scans obtained during the SLS for treatment-associated changes over time.

Methods: Ninety-eight of the 158 subjects (CYC group, 49 subjects; placebo group, 49 subjects) participating in the SLS underwent thoracic HRCT scans both at baseline and after 12 months of treatment, which were available for analysis. Two independent radiologists visually scored the baseline HRCT scans for the presence of ground-glass opacities (GGOs), fibrosis (FIB), and honeycomb cysts (HCs) on a scale of 0 to 4. The treatment effect at 12 months was assessed by a blinded comparison of baseline and follow-up scans for evidence of stability and improvement (not worse) or deterioration (worse).

Results: At the end of treatment, FIB was significantly worse in the placebo treatment group than in the CYC treatment group (p = 0.014). Furthermore, differences in the 12-month change in FIB between the CYC and placebo groups correlated significantly with other outcome measures, including the 12-month changes in FVC (p < 0.05), total lung capacity (p < 0.05), and dyspnea (p < 0.001) scores. However, no differences were noted between the two groups with respect to changes in either GGOs or HCs.

Conclusions: A 1-year course of treatment of SSc-ILD with CYC was associated with treatment-related changes in FIB scores on HRCT scans, which correlated with other measures of treatment response.

Trial Registration: ClinicalTrials.gov Identifier: NCT00004563.

Citing Articles

Mitochondrial and tRNA Gene Variants Associated with Risk and Prognosis of Idiopathic Pulmonary Fibrosis.

Lee L, Jan I, Chou W, Liu W, Kuo Y, Chang C Int J Mol Sci. 2025; 26(3).

PMID: 39941146 PMC: 11818280. DOI: 10.3390/ijms26031378.

Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study.

Panopoulos S, Tzilas V, Bournia V, Tektonidou M, Sfikakis P Rheumatol Int. 2024; 44(10):1959-1966.

PMID: 39180531 DOI: 10.1007/s00296-024-05695-1.

Approval status of essential therapeutic drugs for systemic sclerosis versus that of drugs for rheumatoid arthritis.

Moon K, Hwang S, Yun J, Lee E J Scleroderma Relat Disord. 2024; 9(1):23-28.

PMID: 38333520 PMC: 10848933. DOI: 10.1177/23971983231222368.

Immunomodulatory treatment of interstitial lung disease.

Van den Bosch L, Luppi F, Ferrara G, Mura M Ther Adv Respir Dis. 2022; 16:17534666221117002.

PMID: 35938712 PMC: 9364223. DOI: 10.1177/17534666221117002.

Mycophenolate in scleroderma-associated interstitial lung disease: Real-world data from rheumatology and pulmonology clinics in South Asia.

Janardana R, Irodi A, Chebbi P, Goel R, Vimala L, Padiyar S J Scleroderma Relat Disord. 2022; 6(3):271-276.

PMID: 35387216 PMC: 8922665. DOI: 10.1177/23971983211024410.

References

Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron P . Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology. 1993; 188(2):499-506. DOI: 10.1148/radiology.188.2.8327704. View

Kim D, Yoo B, Lee J, Kim E, Lim C, Lee S . The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19(2):121-7. View

Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti M . Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol. 2002; 29(4):731-6. View

Desai S, Veeraraghavan S, Hansell D, Nikolakopolou A, Goh N, Nicholson A . CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004; 232(2):560-7. DOI: 10.1148/radiol.2322031223. View

Kim H, Li G, Gjertson D, Elashoff R, Shah S, Ochs R . Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol. 2008; 15(8):1004-16. PMC: 2584616. DOI: 10.1016/j.acra.2008.03.011. View

Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D . Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008; 35(6):1064-72. View

Steen V, Medsger Jr T . Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43(11):2437-44. DOI: 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U. View

White B, Moore W, Wigley F, Xiao H, Wise R . Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000; 132(12):947-54. DOI: 10.7326/0003-4819-132-12-200006200-00004. View

. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis. 1990; 141(5 Pt 2):S169-202. DOI: 10.1164/ajrccm/141.5_Pt_2.S169. View

10.

Goldin J, Lynch D, Strollo D, Suh R, Schraufnagel D, Clements P . High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008; 134(2):358-367. DOI: 10.1378/chest.07-2444. View

11.

Mahler D, Weinberg D, Wells C, Feinstein A . The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984; 85(6):751-8. DOI: 10.1378/chest.85.6.751. View

12.

Silver R, Miller K, Kinsella M, Smith E, Schabel S . Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990; 88(5):470-6. DOI: 10.1016/0002-9343(90)90425-d. View

13.

Martinez F, McCune W . Cyclophosphamide for scleroderma lung disease. N Engl J Med. 2006; 354(25):2707-9. DOI: 10.1056/NEJMe068095. View

14.

Pakas I, Ioannidis J, Malagari K, Skopouli F, Moutsopoulos H, Vlachoyiannopoulos P . Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol. 2002; 29(2):298-304. View

15.

Fujita J, Yoshinouchi T, Ohtsuki Y, Tokuda M, Yang Y, Yamadori I . Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis. 2001; 60(3):281-3. PMC: 1753571. DOI: 10.1136/ard.60.3.281. View

16.

Steen V, Conte C, Owens G, Medsger Jr T . Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37(9):1283-9. DOI: 10.1002/art.1780370903. View

17.

Bouros D, Wells A, Nicholson A, Colby T, Polychronopoulos V, Pantelidis P . Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165(12):1581-6. DOI: 10.1164/rccm.2106012. View

18.

Silver R, Warrick J, Kinsella M, Staudt L, Baumann M, Strange C . Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993; 20(5):838-44. View

19.

Wells A . High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford). 2008; 47 Suppl 5:v59-61. DOI: 10.1093/rheumatology/ken271. View

20.

Hoyles R, Ellis R, Wellsbury J, Lees B, Newlands P, Goh N . A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54(12):3962-70. DOI: 10.1002/art.22204. View